Search clinical trials for: CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg

Total 46 results

Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Woman's
AstraZeneca

Completed

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women (DAPA-GDM)

Diabetes Prevention in Women After GDM Who Are at High-risk

United States
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects

Type II Diabetes
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
GlaxoSmithKline

Completed

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Neoplasms, Breast

United States, Korea, Republic of
Dong-A ST Co., Ltd.

Completed

A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers

Type 2 Diabetes Mellitus

Korea, Republic of
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
GlaxoSmithKline

Completed

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

Diabetes Mellitus, Type 2

United States, Taiwan, Argentina, Canada, Philippines, Korea, Republic of, Mexico, Brazil, Pakistan
AstraZeneca
Bristol-Myers Squibb

Completed

A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration (SAXA)

Type 2 Diabetes Mellitus(T2DM)

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
GlaxoSmithKline
Piramal Clinical Research (Hyderabad, India)

Completed

Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions

Ulcers, Duodenal and Gastric

India
GlaxoSmithKline
Piramal Clinical Research (Hyderabad, India)

Completed

Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions

Ulcers, Duodenal and Gastric

India
R-Pharm
GlaxoSmithKline

Terminated

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Locally Advanced or Metastatic Breast Cancer

United States, Italy, Australia
Medical College of Wisconsin
Barbara Ann Karmanos Cancer Institute; Cornerstone Pharmaceuticals

Recruiting

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Ukraine, Argentina, Mexico, Romania, South Africa, Korea, Republic of, Russian Federation, Brazil, Puerto Rico, Hungary, Slovakia, Czechia
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

Healthy

United States
Hoffmann-La Roche

Completed

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

France, Israel, Italy, Spain, Sweden, Hong Kong, Australia, Canada, Switzerland, United States, Ireland, Denmark, Germany, Taiwan, Russian Federation, China, New Zealand, Austria, United Kingdom, Hungary, Thailand, South Africa, Mexico and more
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers

Healthy

Korea, Republic of
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

Healthy

Korea, Republic of
Organon and Co

Completed

A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)

Spondylitis, Ankylosing
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Ohio State University

Not yet recruiting

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

Preterm Birth | Pregnancy, High Risk | Preterm Premature Rupture of Membrane

United States
University of Memphis

Completed

Health Benefits of a 21-day Daniel Fast

Effects of Krill Oil on Human Health

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
Merck Sharp & Dohme LLC
Pfizer

Completed

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

Type 2 Diabetes Mellitus
Bukwang Pharmaceutical

Completed

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Schizophrenia

Korea, Republic of
Royal Marsden NHS Foundation Trust
Hoffmann-La Roche; Professor Cunningham's Clinical Research Fund

Completed

Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer (TARGET)

Pancreatic Cancer

United Kingdom
Eisai Inc.

Completed

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

Healthy Subjects

United States
Mahidol University

Unknown

Efficacy of Adrenaline in Periarticular Analgesic Injection on Postoperative Pain Control After Total Knee Arthroplasty

Postoperative Pain

Thailand
Rabin Medical Center
Tel Aviv University; The Leona M. and Harry B. Helmsley Charitable Trust

Recruiting

Biomarker-based Multidisciplinary Team (Bio-MDT) Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease (Bio-MDT)

Inflammatory Bowel Diseases

Israel
Rambam Health Care Campus

Completed

Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures

Infertility

Israel
Tanta University

Not yet recruiting

Effect of Hebal and Synthetic Medicamentss on Enterococcus Feacalis

Effective Intracanal Medicaments Against Enterococcus Faecalis
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Hannover Medical School

Terminated

Pharmacovigilance in Gerontopsychiatric Patients (GAP)

Depression | Schizophrenia | Anxiety Disorders | Dementia | Psychosomatic Disorders

Germany

3

Subscribe